AgeX Therapeutics Inc.
| AMEX: AGE | Healthcare / Biotechnology / USA |
| 0.7525 | -0.0075 | -0.99% | Vol 30.44K | 1Y Perf 20.63% |
| Sep 22nd, 2023 14:50 DELAYED |
| BID | 0.7250 | ASK | 0.7800 | ||
| Open | 0.7480 | Previous Close | 0.7600 | ||
| Pre-Market | - | After-Market | 0.73 | ||
| - - | -0.02 -2.99% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ☆ 31.25 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 60.59 | Earnings Rating | Neutral | |
| Market Cap | 28.56M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.26 | |
| Beta | 1.70 |
Today's Price Range 0.72570.7900 | 52W Range 0.37201.00 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.75% | ||
| 1 Month | 3.08% | ||
| 3 Months | 10.66% | ||
| 6 Months | 17.58% | ||
| 1 Year | 20.63% | ||
| 3 Years | -14.49% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 1.06M | |||
ROE last 12 Months | 84.32 | |||
ROA (5Y Avg) | -215.75 | |||
ROA last 12 Months | -488.04 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -319.78 | |||
Return on invested Capital Q | -159.39 | |||
Return on invested Capital Y | -179.04 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 2.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.30 | ||||
| 14.33 | ||||
| 901.98 | ||||
| - | ||||
| -4.90 | ||||
| -0.17 | ||||
| -1.51 | ||||
| -0.40 | ||||
| 37.95M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.10 | ||||
| 0.10 | ||||
| 0.41 | ||||
| 0.88 | ||||
| -2.70 | ||||
| Leverage Ratio | -0.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 114.30 | ||||
| -13 713.20 | ||||
| -13 464.20 | ||||
| -22 097.60 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 26.00K | ||||
| 0.00 | ||||
| -68.42 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -0.07 | - |
| Q01 2023 | - | -0.09 | - |
| Q03 2022 | - | -0.06 | - |
| Q02 2022 | - | -0.07 | - |
| Q01 2022 | - | -0.07 | - |
| Q03 2021 | - | -0.05 | - |
| Q02 2021 | - | -0.07 | - |
| Q01 2021 | - | -0.05 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 9th Nov 2023 |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 30.44K |
| Shares Outstanding | 37.95K |
| Shares Float | 18.46M |
| Trades Count | 74 |
| Dollar Volume | 23.41K |
| Avg. Volume | 21.95K |
| Avg. Weekly Volume | 20.17K |
| Avg. Monthly Volume | 21.25K |
| Avg. Quarterly Volume | 24.43K |
AgeX Therapeutics Inc. (AMEX: AGE) stock closed at 0.7525 per share at the end of the most recent trading day (a -0.99% change compared to the prior day closing price) with a volume of 30.44K shares and market capitalization of 28.56M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. AgeX Therapeutics Inc. CEO is Michael D. West.
The one-year performance of AgeX Therapeutics Inc. stock is 20.63%, while year-to-date (YTD) performance is 36.35%. AGE stock has a five-year performance of %. Its 52-week range is between 0.372 and 1, which gives AGE stock a 52-week price range ratio of 60.59%
AgeX Therapeutics Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 14.33, a price-to-sale (PS) ratio of 901.97, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -488.04%, a ROC of -319.78% and a ROE of 84.32%. The company’s profit margin is -%, its EBITDA margin is -13 464.20%, and its revenue ttm is $26.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from AgeX Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. AgeX Therapeutics Inc.’s next earnings report date is 09th Nov 2023.
The consensus rating of Wall Street analysts for AgeX Therapeutics Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for AgeX Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AgeX Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AgeX Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 27.89, ATR14 : 0.07, CCI20 : 38.77, Chaikin Money Flow : 0.13, MACD : 0.00, Money Flow Index : 63.21, ROC : 7.50, RSI : 50.01, STOCH (14,3) : 53.13, STOCH RSI : 0.34, UO : 57.24, Williams %R : -46.87), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AgeX Therapeutics Inc. in the last 12-months were: Michael D. West (Option Excercise at a value of $0), West Michael (Option Excercise at a value of $0)
AgeX Therapeutics Inc.
AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develop innovative medicines designed to address some of the unsolved problems in aging. Its PureStem derived cell-based therapeutic candidates in development are AGEX-VASC1 and AGEX-BAT1. And iTR drug-based therapeutic candidates in development are AGEX-iTR1547 and Renelon.
CEO: Michael D. West
Telephone: +1 510 871-4190
Address: 1010 Atlantic Avenue, Alameda 94501, CA, US
Number of employees: 17
